Deutsche Bank AG Acquires 1,031,998 Shares of CVS Health Corporation $CVS

11 Jun 2026, 04:17 by Doug Wharley · The Cerbat Gem

Deutsche Bank AG raised its holdings in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 28.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 4,666,495 shares of the pharmacy operator’s stock after purchasing an additional 1,031,998 shares during the period. Deutsche Bank AG’s holdings in CVS Health were worth $370,333,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brandes Investment Partners LP boosted its holdings in CVS Health by 2.5% in the fourth quarter. Brandes Investment Partners LP now owns 1,845,342 shares of the pharmacy operator’s stock worth $146,447,000 after acquiring an additional 45,860 shares in the last quarter. Motley Fool Asset Management LLC boosted its holdings in CVS Health by 30.1% in the fourth quarter. Motley Fool Asset Management LLC now owns 129,763 shares of the pharmacy operator’s stock worth $10,298,000 after acquiring an additional 30,027 shares in the last quarter. Stonebrook Private Inc. boosted its holdings in CVS Health by 6.3% in the fourth quarter. Stonebrook Private Inc. now owns 3,449 shares of the pharmacy operator’s stock worth $274,000 after acquiring an additional 204 shares in the last quarter. Alteri Wealth LLC boosted its holdings in CVS Health by 41.0% in the fourth quarter. Alteri Wealth LLC now owns 5,913 shares of the pharmacy operator’s stock worth $469,000 after acquiring an additional 1,718 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC boosted its holdings in CVS Health by 5.9% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 20,451 shares of the pharmacy operator’s stock worth $1,623,000 after acquiring an additional 1,135 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. TD Cowen boosted their target price on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Deutsche Bank Aktiengesellschaft boosted their target price on CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. DA Davidson boosted their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Sanford C. Bernstein boosted their target price on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. boosted their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and a consensus target price of $100.68.

Get Our Latest Research Report on CVS

CVS Health Trading Up 1.1%

Shares of NYSE:CVS opened at $98.10 on Thursday. The company has a market cap of $125.16 billion, a P/E ratio of 43.21, a PEG ratio of 0.95 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $98.61. The stock’s fifty day moving average price is $85.75 and its 200-day moving average price is $80.47.

CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

Insiders Place Their Bets

In related news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the sale, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight management medications, which could improve access for members and support pharmacy benefit growth while reinforcing CVS’s role in a high-demand therapeutic category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options
Positive Sentiment: Investor sentiment also improved after commentary that CVS is in a meaningful turnaround, with recent results showing stronger insurance performance and improving retail pharmacy market share. CVS Offers A Compelling Turnaround Opportunity Not Seen In Years
Positive Sentiment: CVS was recognized for technology that improves medication safety and patient care, supporting the company’s long-term narrative around innovation and healthcare delivery efficiency. CVS Health Recognized for Technology That Improves Medication Safety and Patient Care
Neutral Sentiment: CVS named Zach Dennett as interim merchandising leader after Musab Balbale departed the company, a leadership change that may draw attention but is not clearly material on its own. Musab Balbale Departs CVS Health; Zach Dennett Named Interim Merchandising Leader
Neutral Sentiment: CVS also announced an AI Learning Academy for employees, underscoring ongoing investments in automation and workforce training, though the near-term stock impact is likely limited. CVS launched an AI Learning Academy for its workforce. Here’s why
Negative Sentiment: Reports that major hospitals are suing CVS over an alleged drug discount scheme could raise legal and reputational risks, which may pressure the stock if the case gains traction. Major hospitals sue CVS over alleged drug discount scheme

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.